Chairman of the Board
Immuneo Therapeutics GmbH
Germany
Dr. Wolfgang Schönharting brings a multidisciplinary background to his pioneering work in cancer immunotherapy and vaccine development. He studied mathematics, physics, and computer science at the Technical University of Munich, and life sciences at LMU Munich. He completed his PhD at the University of Bremen on a prestigious scholarship and later obtained a law degree, qualifying as a fully licensed lawyer.
Driven by a personal encounter with unmet medical needs in traditional cancer therapies, Dr. Schönharting shifted his focus to medical cybernetics. His work has since spanned cellular and molecular biology, immunology, and the development of innovative therapeutic approaches. His primary scientific interest lies in the design of immunization strategies against cancer and infectious diseases, emphasizing the prediction of immunogenic neo-antigens and their association with metabolic and pathological patterns for therapeutic and prophylactic applications.
With over a decade of dedicated research, Dr. Schönharting's efforts culminated in the founding of IMMUNEO Therapeutics GmbH in 2017. As Chairman of the Board, he continues to lead the organization in advancing novel cancer therapies and immunization solutions aimed at transforming clinical outcomes.